ExLibris header image
SFX Logo
Title: Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders
Source:

Molecules [1420-3049] Waltenberger, Birgit yr:2016


Collapse list of basic services Basic
Full text
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Neschen, S. "Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 (SGLT2) inhibitor by suppressing endogenous glucose production in diabetic mice." Diabetes 64.1 (2014): 284-393. Link to SFX for this item
2. Xu, X. "Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment." Molecular pharmaceutics 12.11 (2015): 4294967295-91. Link to Full Text for this item Link to SFX for this item
3. Foretz, M. "Metformin: From Mechanisms of Action to Therapies." Cell metabolism 20.6 (2014): 953-966. Link to SFX for this item
4. Over, Rebecca K K. "Combination pharmacotherapy with incretins: what works best and when?" Current Diabetes Reports 8.5 (2008): 361-7. Link to SFX for this item
5. Jayakumari N.R.. "Are nitric oxide-mediated protein modifications of functional significance in diabetic heart? ye'S, -NO', wh'Y-NO't?" Nitric oxide 43 (2014): 35-. Link to SFX for this item
6. Korbonits, M. "Metformin-mode of action and clinical implications for diabetes and cancer." Nature reviews. Endocrinology 10.3 (2014): 143-156. Link to SFX for this item
7. Viollet, B. "Cellular and molecular mechanisms of metformin: an overview." Clinical science 122.6: 253-270. Link to SFX for this item
8. Hong, Y. "The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea." PloS one. 14.7. Link to SFX for this item
9. The British journal of nutrition. 114.10: 1667-1673. Link to SFX for this item
10. He, H. "Metformin, an Old Drug, Brings a New Era to Cancer Therapy." The cancer journal 21.2 (2015): 70-74. Link to SFX for this item
11. Qaseem, A. "Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine 156.3 (2012): 218-231. Link to SFX for this item
12. Nayak, U A. "Exenatide therapy in insulin-treated type 2 diabetes and obesity." QJM 103.9 (2010): 687-694. Link to SFX for this item
13. Nissen, Steven E. "Angiotensin-receptor blockers and cancer: urgent regulatory review needed." The lancet oncology 11.7 (2010): 605-606. Link to SFX for this item
14. Yoon, Nancy M. "Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting." Clinical therapeutics 31.7 (2009): 1511-1523. Link to SFX for this item
15. Rosenstock, J. "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)." The Lancet 374.9683 (2009): 39-47. Link to SFX for this item
16. Knudsen, L B B. "Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor." European journal of pharmacology 318.2-3: 429-435. Link to SFX for this item
17. Morris, A D D. "Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines." Diabetic medicine 18.6 (2001): 483-8. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.